Turn updates investor presentation, cites Q4 2026 AD Phase 2 topline and $11.2M cash

Turn released an updated investor presentation highlighting a Q4 2026 topline readout for GX-03 and a cash balance of $11.2M as of March 31, 2026.

Key Highlights:

• Furnished updated investor presentation as Exhibit 99.1 under Regulation FD disclosure.
• GX-03 Phase 2 in moderate-to-severe atopic dermatitis: topline readout expected Q4 2026; Phase 3 initiation mid-2027.
• Reported clinical signals from Stage 2 interim: Week 4 vIGA success 61.5% vs 8.3% (Δ 53.2%, p=0.0100) in a representative subgroup.
• Pipeline milestones: onychomycosis Phase 3 ready with Phase 3 initiation Q1 2027 and planned topline in Q4 2028.
• Financials and IP: $11.2M cash, ~29.8M shares outstanding, cash runway into Q3 2027 and multiple issued patents through 2040.

Original SEC Filing:

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.